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PURPOSE. To correlate changes in choroidal thickness and vascularity index with disease
activity in patients with neovascular age-related macular degeneration (nAMD).
METHODS. Eyes diagnosed with AMD that had two sequential visits within 12 months and that
had no choroidal neovascularization (CNV) or had inactive CNV at the first visit were
included. Those that had active CNV at follow-up were enrolled as cases. Eyes that did not
developed a CNV or that were still inactive at the second visit were enrolled as controls.
Disease activity was based on optical coherence tomography (OCT) and fluorescein
angiography findings. Subfoveal choroidal thickness (SCT), mean choroidal thickness
(MCT), and choroidal vascularity index (CVI) were assessed on enhanced depth imaging
OCT and compared between the baseline and follow-up visit. Subgroup analysis accounting
for lesion type and previous treatment, if any, were performed.
RESULTS. Sixty-five eyes from 60 patients (35 females) and 50 age- and sex-matched controls
were included. At the active visit, cases had an increase from 164 6 67 lm to 175 6 70 lm in
mean 6 SD SCT and from 1446 45 lm to 152 6 45 lm in MCT (both P < 0.0001). The mean
CVI also increased at from 54.5% 6 3.3% to 55.4% 6 3.8% (P ¼ 0.04). Controls did not show
significant changes in choroidal measurements between the two visits. Mean SCT, MCT, and
CVI values were similar for previously treated and treatment-naive eyes.
CONCLUSIONS. Choroidal thickness and CVI significantly increased with active disease in nAMD
eyes. Changes in choroidal thickness may predict CNV development or recurrence before
they are otherwise evident clinically.
Keywords: choroid, neovascular age related macular degeneration, EDI-OCT, choroidal
vascularity index, CNV activity
The blood flow within the choroid is influenced by severalphysiological processes and pathological conditions.1,2 An
increase in choroidal flow may be due to purely mechanical
processes induced by systemic hemodynamic changes or from a
local response to various locally or systemically generated
chemical stimuli.3
A strong correlation exists between ageing and choroidal
thinning, most likely due to progressive loss of tissue and
vascular narrowing.4 This process, along with the reduced
Bruch’s membrane permeability that is found with increasing
age, impairs the oxygen supply to the retina.5 Retinal and
retinal pigment epithelial cells release vascular endothelial
growth factor (VEGF) to dilate the choroidal vessels and
increase the blood flow, but this may also lead to choroidal
neovascularization (CNV).6–8 The association of intraocular
VEGF levels and choroidal blood flow is further supported by
the choroidal thinning that is detected in eyes receiving
intravitreal anti-VEGF therapy for neovascular age-related
macular degeneration (nAMD).9,10
Choroidal thickening may, therefore, occur in the active
phase of nAMD due to increased levels of VEGF and other
proinflammatory factors together with hydrostatic variation in
the blood flow within the newly formed vessels.11 We propose
that choroidal thickness might be a useful marker to predict the
development of new CNV or reactivation of CNVs which have
been rendered inactive with treatment, before they are
otherwise evident clinically.
The aim of this study was to correlate changes in choroidal
thickness and vascularity index, a reliable method to calculate
the ratio between the intravascular space and the choroidal
stroma,6,12 with disease activity in patients with nAMD.13
MATERIALS AND METHODS
The clinical records from patients diagnosed with intermediate
AMD (drusen and retinal pigment epithelium mottling only) or
nAMD and followed at two tertiary centers in the north of Italy
(Eye Clinic, Luigi Sacco Hospital, University of Milan, and
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Ophthalmological Unit, IRCCS-Ca` Granda Foundation–Ospe-
dale Maggiore Policlinico, Milan) between January 2015 and
December 2016 were reviewed. Institutional Review Board/
Ethics Committee approval was obtained for the study prior to
its commencement. The study adhered to the tenets of the
Declaration of Helsinki.
Eyes had to have two consecutive visits within 12 months
with no signs of neovascular activity at the first visit (baseline)
to be included. Absence of neovascular activity was defined as
no history of CNV (i.e., drusen or retinal pigment epithelium
only) or presence of a CNV that had received no treatment for
3 months and still had no signs of activity on OCT (no
intraretinal/subretinal fluid) and on fundus fluorescein angiog-
raphy (no leakage or blood). The 3-month interval was
established on the basis of the pharmacokinetics of anti-VEGF
agents in the eye14 and the levels of circulating VEGF following
intravitreal anti-VEGF treatments15 in order to minimize drugs
effect on the choroid.
Eyes that developed a new CNV or showed a re-activation of
the pre-existing CNV (activity was defined as presence of fluid
on OCT and/or leakage or blood on fundus fluorescein
angiography) at the second visit (follow-up) were enrolled as
cases. Eyes that were still inactive at follow-up visit were
enrolled as controls.
The patients had to have the same (true-track based)
enhanced depth optical coherence tomography (EDI-OCT)
horizontal single line scan (Heidelberg Engineering, Heidel-
berg, Germany) encompassing the fovea at inactive and active
disease visits to be included. EDI-OCT images were collected all
between 9.00 AM and 12.00 AM as part of the standard clinical
evaluation, thus limiting the effect of circadian rhythm on
choroidal thickness.1
EDI-OCT images were used to perform two different
evaluations of the choroid: choroidal thickness analysis and
choroidal vascularity index (CVI) calculation.
Choroidal thickness was assessed by two independent
skilled operators (EB and MC) with the OCT software (Eye
Explorer version 1.9.10.0, Heidelberg Engineering) embedded
caliper tool at three different locations: underneath the fovea, 3
mm nasally, and 3 mm temporally (Fig. 1). Interobserver
agreement was calculated, and measurements from the first
operator (EB) were used for the study analysis.
The CVI, defined as the ration of luminal area an total
choroidal area, was calculated using a previously described
FIGURE 1. Choroidal thickness analysis in a patient with inactive CNV
due to nAMD. Choroidal thickness was assessed with the OCT software
(Eye Explorer version 1.9.10.0, Heidelberg Engineering) embedded
caliper tool at three different locations: underneath the fovea, 3 mm
nasally, and 3 mm temporally. The central measurement was
considered in the analysis as SCT, whereas the mean of the three
measurements was calculated to obtain an averaged measure of the
choroidal thickness across the posterior pole (MCT).
FIGURE 2. CVI calculation in a patient affected by AMD. Multimodal
images were exported from the Eye Explorer Software and cropped in
order to obtain single EDI-OCT scans (A). Choroidal boundaries were
automatically identified (yellow lines). Manual corrections were
applied in case of segmentations artifacts (B). The selected part of
the image, corresponding to the choroid, was then binarized (C). This
process allowed to calculate a black/white ratio representing the CVI.
FIGURE 3. Choroidal thickness changes in a patient affected by nAMD
at different phases of disease activity. At baseline (A) the disease
appears inactive. The inner choroidal boundary (Bruch’s membrane) is
marked with a blue dotted line. The outer choroidal boundary
(choroido-scleral interface) is marked with a red dotted line. At
follow-up visit (B) subretinal and intraretinal fluid is visible as a sign of
active disease. At this time the inner and outer choroidal boundaries
are marked with a blue and a red continue line, respectively. In a
graphic representation overlapping the lines tracked along the Bruch’s
membrane at baseline and follow-up visit (C), it is evident how the red
continuous line representing the outer boundary of the choroid during
the active stages of the disease lays underneath the baseline one. The
gap between the two corresponds to the choroidal thickening
occurred along with the choroidal neovascular membrane reactivation.
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algorithm.16 Briefly, choroidal stroma and vessel area analysis
involved (1) automated binarization of a high definition
horizontal 6-mm OCT B-scan and (2) automated segmentation
of the binarized choroid layer as reported previously. The task
of automated binarization in turn involved (a) preprocessing,
(b) exponential and nonlinear enhancement, and (c) thresh-
olding (Fig. 2).
Measurements were performed on the images collected at
inactive and active stage and then compared with each other.
Patients were subsequently grouped according to CNV type
(classified into type 1, type 2, or type 3 according to fundus
fluorescein angiography (FFA) and OCT appearance).17,18
Minimally classic CNVs were grouped into type 1 lesions,
whereas predominantly classic were considered as type 2.
Treatment previously received was also recorded (treatment
na¨ıve, ranibizumab, aflibercept) for further subanalysis.
Statistical Analysis
Interobserver agreement for choroidal thickness measure-
ments was assessed using an intraclass correlation coefficient
(ICC). Mean choroidal thickness (MCT; average of the three
measurements), subfoveal choroidal thickness (SCT), and CVI
values were compared between baseline and follow-up visits
by paired t-test both in cases and controls. The same analysis
was performed in each CNV type subgroup and in pretreat-
ment-based subgroups.
MCT, SCT, and CVI at baseline (inactive) and follow-up
(active) visits were compared among the patients diagnosed
with different CNV types in the cases group through pairwise
comparisons. The same analysis was also performed to
compare patients who had received different treatments. The
possible effect of time interval between the two visits on the
change in choroidal measurements was tested using linear
regression model.
Both eyes of the same patient could be enrolled in the study
in case they both met the inclusion criteria. For this reason, the
entire analysis was repeated after one of the two eyes from
each of the subject that contributed with both eyes had been
randomly excluded. Statistical analysis was performed using R
statistical package version 3.3.1 (R Project–The R Foundation
for Statistical Computing; http://www.R-project.org). A P value
< 0.05 was considered to be statistically significant.
RESULTS
Sixty-five eyes from 60 patients (35 females) were included in
the study as cases. The mean 6 standard deviation (SD) age
was 80.5 6 6.4 (range, 66–93) years. There were 32 type 1, 17
type 2, and 16 type 3 CNV lesions. At the designated inactive
visits, 22 eyes had intermediate dry AMD with no history of
CNV. Among the 43 that had a CNV with no sign of activity, 34
had previously received ranibizumab and nine had received
aflibercept.
The control group comprised 50 patients (28 females),
mean age 78.8 6 7.2 (range, 60–95) years. In this group, 27
had no sign of CNV (drusen and retinal pigment epithelium
mottling only) and 23 had inactive CNV at both visits.
The ICC for interobserver agreement for choroidal thick-
ness measurements was 0.89 (confidence interval, 0.86–0.90).
In the cases group, the baseline (inactive) visit mean 6 SD
SCT was 164 6 67 lm and mean 6 SD MCT was 144 6 45 lm.
These measurements increased to 175.1 6 70 lm and 152.3 6
FIGURE 4. Graphical representation of SCT change according to disease activity in patients affected by AMD divided by lesion type. SCT (mean 6
SD) significantly increased in the entire population from 164 6 67 lm to 175 6 70 lm on average (P < 0.0001). Subgroup analysis based on lesion
type showed a significant increase in SCT in all three groups with CNVs type 1 having the most significant increase.
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45 lm, respectively, at the follow-up (active) visit (both P <
0.0001) (Figs. 3, 4; Supplementary Video S1). The mean 6 SD
CVI also increased in the cases group from 54.5% 6 3.3% in
inactive eyes to 55.4% 6 3.8% in active CNVs (P ¼ 0.04) (Fig.
5). The same measurements did not change significantly from
baseline to follow-up visit in the controls group. Detailed data
about choroidal measurements at the baseline and follow-up
visit in both cases and controls are presented in Table 1. The
mean 6 SD interval between the baseline and the follow-up
visit was 113 6 68 (range, 28–328) days among the cases and
142 6 75 (range, 52–350) in the controls. There was no
significant effect of the time interval on the variation of any of
the choroidal measurements (all P > 0.45).
There was no significant difference in terms of SCT, MCT,
and CVI between treatment na¨ıve, ranibizumab, or aflibercept
treated patients (all P > 0.05) both at the inactive and active
visits. Mean SCT and MCT significantly increased at the active
visits regardless of whether or not eyes had received treatment
before or which agent had been used if they had. CVI increased
at the active visit in all the three treatment groups, but this
change was only statistically significant for the treatment-na¨ıve
group (P ¼ 0.02). Detailed data on choroidal measurements
according to treatment previously received are presented in
Table 2.
Type 3 lesions had a significantly thinner mean SCT and
MCT compared with type 1 CNVs at both the inactive and
active visits. There was no difference in CVI among the
different lesions types. The change in SCT and MCT from
inactive to active visits was statistically significant for all the
three lesion types. Only type 1 lesions showed a significant
increase in CVI from the inactive to the active visits (P¼ 0.02).
Detailed data on choroidal measurements according to CNV
type are presented in Table 3.
The sensitivity analysis performed repeating the tests after
removing one eye from each patient that contributed with
both eyes to the study did not give significantly different results
from the ones reported above.
DISCUSSION
In this study we analyzed changes in the choroid of eyes
diagnosed with nAMD before and after the development or
reactivation of CNV and in a group of control eyes that did not
develop a CNV or that had a persistently inactive disease. We
found that the presence of an active CNV was associated with
an increase in SCT, MCT, and vascularity index regardless of the
lesion type or whether or not the eye had been treated in the
past. These changes were not seen in controls.
Several studies have reported choroidal thinning during
anti-VEGF therapy.9,10,19 Kim et al.20 demonstrated that, after
the initial shrinkage caused by anti-VEGF treatment, the
choroidal thickness progressively increases as the drug
wears off and then thins again with further anti-VEGF
administration. A recent study also demonstrated that eyes
receiving anti-VEGF therapy with a pro re nata regimen 1
year after starting the treatment have thinner choroids
compared with baseline.9 However, limited data are available
on the choroidal changes occurring before an active CNV
becomes clinically evident. Treatment na¨ıve eyes in the
present analysis had increased choroidal flow after the CNV
had been diagnosed, whereas no changes in the choroidal
measurements were identified in the eyes that did not
FIGURE 5. CVI changes in a patient affected by AMD during the inactive and active phases of the disease. Baseline EDI-OCT scan (A) showed the
presence of an inactive CNV under the fovea. The EDI-OCT scan of the same patient during the follow-up visit demonstrating subretinal fluid as a
sign of activity is reported (B). Corresponding binarized images of the choroid during the inactive (C) and the active/recurrent (D) stage of the
disease are reported. CVI resulting from the ration between black/white pixels changed from 43% at baseline to 48% at follow-up examination.
TABLE 1. Choroidal Measurements in Patients Diagnosed With nAMD With Inactive and Active Disease
Cases, n ¼ 65 Inactive Active Change P Value*
SCT, mean 6 SD 164 6 67 lm 175 6 70 lm 12 6 12 lm <0.0001
MCT, mean 6 SD 144 6 45 lm 152 6 45 lm 10 6 8 lm <0.0001
CVI, mean 6 SD 54.5% 6 3.3% 55.4% 6 3.8% 0.9% 6 3.5% 0.04
Controls, n ¼ 50 Baseline Follow-up Change P Value*
SCT, mean 6 SD 175 6 70 lm 174 6 70 lm 0.8 6 7 lm 0.42
MCT, mean 6 SD 156 6 44 lm 155 6 45 lm 0.4 6 6 lm 0.63
CVI, mean 6 SD 55.8% 6 3.4% 55.4% 6 3.6% 0.3% 6 2.9% 0.58
Statistically significant P values are reported in bold.
* Paired t-test.
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develop a CNV. This offers a new insight in the pathophys-
iology of the disease and in a possible role of choroidal
parameters in the earlier diagnosis of CNV lesions.
We included eyes that had received anti-VEGF agents in the
past for CNV. We prespecified a minimum 3 months treatment-
free interval, based on the pharmacokinetics of the current
VEGF inhibitors,14 before the inactive visit as an inclusion
criterion to minimize the effect of pretreatment on our results.
We did not find any difference in choroidal thickness at
inactive or at active visits between treatment na¨ıve patients and
those that had previously received ranibizumab or aflibercept.
Since it has been reported that VEGF inhibitors thin the
choroid, it appears that the effect of previous treatment had
worn off at the inactive (baseline) examination. These findings
suggest that the choroidal thickening that we observed at the
active visits depended more on the reactivation of the CNV
rather that on a decrease in the concentration of the drug
within the eye.
We performed three different measurements to assess the
changes in the choroidal perfusion indirectly, all of which
showed a significant increase from the inactive to the active
visits. The subfoveal thickness measurement demonstrated the
most significant shift during the active phase of the disease in
the entire cohort. This might be expected, since most of the
CNVs in nAMD are located within the central macula.21 The
vasculature located in this area, as a consequence, experiences
maximal exposure to the mechanical variations in the blood
flow occurring within the newly formed vessels. The levels of
inflammatory cytokines and VEGF are also likely to be highest
close to the CNV. However, CVI and MCT reflect changes in the
choroidal vasculature across the whole posterior pole and they
also increased when the CNV was active. We are unable to say
whether the vascular changes involve just the area around the
CNV or the entire choroid.12
We found significant choroidal thickening in all CNV types,
but only type 1 lesions showed significant changes in CVI from
the inactive to the active phase of the disease. Perhaps this is
because the neovascular network of type 1 CNVs is beneath
the RPE,17 which may limit the diffusion of inflammatory
mediators and VEFGs toward the retina, thereby enhancing
their concentration within the choroid.22 This speculation is
supported by the fact that type 3 lesions showed less obvious
changes compared to the other CNV types in all the choroidal
parameters we assessed. In these eyes with type 3 CNV, the
anastomosis between the retinal and the choroidal vasculature
could in fact favor the drainage of blood through the retinal
vessels, thereby decreasing cytokines levels and the vascular
congestion within the choroid.23
Reduced choroidal thickness has been reported in
patients with type 3 lesions compared with age-matched
controls.8 Interestingly, we found patients with type 3 CNVs
had thinner choroids than the other CNV types regardless of
the disease activity, which was statistically significant when
comparing them to patients with type 1 CNVs. Patients
developing type 3 lesions are usually older,23 which might
explain our finding since age and choroidal thickness are
known to be negatively correlated.4 Choroidal hypo-perfu-
sion has been previously reported in type 3 CNVs.24 Hypo-
perfusion would be expected to induce choroidal thinning,
further supporting our findings.
Ahn et al.19 described a progressive thickening of the
choroid before the CNV reactivation in a longitudinal study on
TABLE 2. Choroidal Measurements in Patients Diagnosed With nAMD With Inactive and Active Disease Divided by Previously Received Treatment
Naı¨ve, n ¼ 22 Ranibizumab, n ¼ 34 P Value* Aflibercept, n ¼ 9 P Value* P Value†
Inactive SCT, mean 6 SD 152 6 49 lm 165 6 73 lm 0.77 190 6 79 lm 0.33 0.58
Active SCT, mean 6 SD 163 6 54 lm 175 6 76 lm 0.81 206 6 77 lm 0.27 0.46
P value‡ 0.002 <0.0001 0.01
Inactive MCT 138 6 33 lm 145 6 50 lm 0.81 154 6 50 lm 0.63 0.86
Active MCT 147 6 35 lm 153 6 51 lm 0.89 164 6 53 lm 0.62 0.78
P value‡ <0.0001 <0.0001 0.05
Inactive CVI 52.7% 6 3.6% 55.49% 6 2.9% 0.08 54.9% 6 2.4% 0.20 0.88
Active CVI 54.9% 6 3.3% 55.7% 6 4.4% 0.74 55.5% 6 2.6% 0.92 0.98
P value‡ 0.02 0.6 0.4
Statistically significant P values are reported in bold.
* Pairwise comparisons analysis (P values are referred to comparisons with treatment na¨ıve eyes).
† Pairwise comparisons analysis (P values are referred to comparisons with eyes that had been treated with ranibizumab).
‡ Paired t-test comparing inactive and active visit.
TABLE 3. Choroidal Measurements in Patients Diagnosed With nAMD With Inactive and Active Disease Divided by Lesion Type
Type 1 CNV, n ¼ 32 Type 2 CNV, n ¼ 17 P Value* Type 3 CNV, n ¼ 16 P Value* P Value†
Inactive SCT, mean 6 SD 178 6 71 lm 173 6 66 lm 0.96 126 6 43 lm 0.02 0.09
Active SCT, mean 6 SD 189 6 73 lm 184 6 69 lm 0.95 137 6 50 lm 0.03 0.12
P value‡ <0.0001 0.003 0.02
Inactive MCT 153 6 48 lm 150 6 45 lm 0.97 120 6 26 lm 0.04 0.12
Active MCT 160 6 48 lm 161 6 45 lm 0.99 126 6 30 lm 0.03 0.06
P value‡ 0.0007 0.0004 0.04
Inactive CVI 54.6% 6 3.2% 55.2% 6 2.7% 0.82 53.4% 6 3.9% 0.46 0.26
Active CVI 56% 6 3.9% 54.8% 6 4.1% 0.57 54.9% 6 3.2% 0.66 0.99
P value‡ 0.02 0.6 0.1
Statistically significant P values are reported in bold.
* Pairwise comparisons analysis (P values are referred to comparisons with type 1 CNV).
† Pairwise comparisons analysis (P values are referred to comparisons with type 2 CNV).
‡ Paired t-test comparing inactive and active visit.
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myopic CNVs treated with anti-VEGF. In our study we had only
two time points when the choroid was measured and we did
not find any effect of the time interval between the visits on
the choroidal changes magnitude. A possible explanation is
that the CNV had already reactivated when the second visit
was performed in our study. As a consequence, the shift in the
choroidal measurements was always measured at its peak with
the increase not necessarily being directly correlated with the
time to re-activation. A longitudinal study is needed to track
progressive changes of the choroidal indices before the CNV
reactivates.19
We wish to acknowledge several limitations of this study. Its
retrospective nature limited the regularity of follow-up
examinations, which were therefore not conducted at the
same time. The relatively small sample size precluded a
multivariate analysis that might have accounted for factors
such as the patients’ age or gender. Finally, the choroidal
thickness was measured manually. Despite good interobserver
agreement, this method can still be affected by the operator
skills.
To conclude, we have demonstrated that the choroid
increases in thickness as well as vascularity in patients with
nAMD as CNV develop or reactivate. Choroidal thickening and
increasing CVI reflect an increase in choroidal blood flow,
which may have different causes. Further studies are needed to
confirm our findings and to assess the possible role of
choroidal changes as earlier predictors of new or reactivating
CNV in nAMD.
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SUPPLEMENTARY MATERIAL
SUPPLEMENTARY VIDEO. Choroidal thickness increase during
the active stage of nAMD. Sequential OCT scans encompassing
the foveal region in an eye affected by nAMD are presented in
the form of a movie. The sequence allows one to appreciate
the increased choroidal thickness characterizing the active
stage of the disease.
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